(VIANEWS) – Krystal Biotech (KRYS), Catalyst Pharmaceuticals (CPRX), Advanced Semiconductor Engineering (ASX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Krystal Biotech (KRYS)
127.5% sales growth and 14.2% return on equity
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Earnings Per Share
As for profitability, Krystal Biotech has a trailing twelve months EPS of $3.94.
PE Ratio
Krystal Biotech has a trailing twelve months price to earnings ratio of 46.75. Meaning, the purchaser of the share is investing $46.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.2%.
Volume
Today’s last reported volume for Krystal Biotech is 86190 which is 78.21% below its average volume of 395720.
Sales Growth
Krystal Biotech’s sales growth is 883.8% for the present quarter and 127.5% for the next.
2. Catalyst Pharmaceuticals (CPRX)
16.7% sales growth and 13.85% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.63.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 24.16. Meaning, the purchaser of the share is investing $24.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.85%.
Sales Growth
Catalyst Pharmaceuticals’s sales growth is 23% for the ongoing quarter and 16.7% for the next.
Moving Average
Catalyst Pharmaceuticals’s worth is way below its 50-day moving average of $17.88 and under its 200-day moving average of $15.88.
Revenue Growth
Year-on-year quarterly revenue growth grew by 23.2%, now sitting on 434.48M for the twelve trailing months.
Yearly Top and Bottom Value
Catalyst Pharmaceuticals’s stock is valued at $15.22 at 06:22 EST, way below its 52-week high of $20.87 and way above its 52-week low of $11.55.
3. Advanced Semiconductor Engineering (ASX)
15.8% sales growth and 10.76% return on equity
ASE Technology Holding Co., Ltd., together with its subsidiaries, provides semiconductors packaging and testing, and electronic manufacturing services in the United States, Taiwan, Asia, Europe, and internationally. It develops, constructs, sells, leases, and manages real estate properties; produces substrates; offers information software, equipment leasing, investment advisory, and warehousing management services; commercial complex, after-sales, and support services; manages parking lot services; processes and sells computer and communication peripherals, electronic components, telecommunications equipment, and motherboards; and imports and exports goods and technology. ASE Technology Holding Co., Ltd. was founded in 1984 and is based in Kaohsiung, Taiwan.
Earnings Per Share
As for profitability, Advanced Semiconductor Engineering has a trailing twelve months EPS of $0.5.
PE Ratio
Advanced Semiconductor Engineering has a trailing twelve months price to earnings ratio of 21.7. Meaning, the purchaser of the share is investing $21.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.76%.
4. ExlService Holdings (EXLS)
14.4% sales growth and 21.19% return on equity
ExlService Holdings, Inc. operates as a data analytics, and digital operations and solutions company in the United States and internationally. The company operates through Insurance, Healthcare, Analytics, and Emerging Business segments. It also provides digital operations and solutions and analytics-driven services, such as claims processing, premium and benefit administration, agency management, account reconciliation, policy research, underwriting support, new business acquisition, policy servicing, premium audit, surveys, billing and collection, commercial and residential survey, and customer service using digital technology, artificial intelligence, machine learning, and advanced automation; digital customer acquisition services using a software-as-a-service delivery model through LifePRO and LISS platforms; subrogation services; and Subrosource software platform, an end-to-end subrogation platform. In addition, the company offers health care services related to care management, utilization management, disease management, payment integrity, revenue optimization, and customer engagement. Further, it provides financial planning and analysis, management reporting, forecasting and decision support, data management, regulatory reporting and risk, and compliance services; reservations, customer, and fulfilment services; freight billing, collections, claims management, freight audit, freight scheduling, supply chain management, and revenue assurance services; residential mortgage lending, title verification and validation, retail banking and credit cards, trust verification, commercial banking, and investment management; merchandising, pricing, and demand forecasting; and digital operations and solutions. The company offers predictive and prescriptive analytics in the areas of customer acquisition and lifecycle management. ExlService Holdings, Inc. was founded in 1999 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, ExlService Holdings has a trailing twelve months EPS of $1.08.
PE Ratio
ExlService Holdings has a trailing twelve months price to earnings ratio of 33.83. Meaning, the purchaser of the share is investing $33.83 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.19%.
Volume
Today’s last reported volume for ExlService Holdings is 1155290 which is 19.53% above its average volume of 966519.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.7%, now sitting on 1.71B for the twelve trailing months.
Sales Growth
ExlService Holdings’s sales growth is 13.9% for the current quarter and 14.4% for the next.
5. International General Insurance Holdings Ltd. (IGIC)
11% sales growth and 21.7% return on equity
International General Insurance Holdings Ltd. provides specialty insurance and reinsurance solutions worldwide. The company operates through three segments: Specialty Long-tail, Specialty Short-tail, and Reinsurance segments. It offers a portfolio of specialty lines insurance products and services for energy, property, construction and engineering, ports and terminals, general aviation, political violence, casualty, financial institutions, marine liability, and treaty reinsurance. The company was founded in 2001 and is based in Amman, Jordan.
Earnings Per Share
As for profitability, International General Insurance Holdings Ltd. has a trailing twelve months EPS of $2.51.
PE Ratio
International General Insurance Holdings Ltd. has a trailing twelve months price to earnings ratio of 7.1. Meaning, the purchaser of the share is investing $7.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.7%.
Yearly Top and Bottom Value
International General Insurance Holdings Ltd.’s stock is valued at $17.82 at 06:22 EST, under its 52-week high of $18.74 and way higher than its 52-week low of $10.68.
Volume
Today’s last reported volume for International General Insurance Holdings Ltd. is 55640 which is 29.25% below its average volume of 78651.
6. Bank OZK (OZK)
8.3% sales growth and 13.74% return on equity
Bank OZK provides various retail and commercial banking services. The company accepts various deposit products, including non-interest-bearing checking, interest bearing transaction, business sweep, savings, money market, individual retirement, and other accounts, as well as time deposits. It also offers real estate, consumer and business purpose, indirect recreational vehicle and marine, commercial and industrial, government guaranteed, agricultural equipment, small business, lines of credit, homebuilder, and affordable housing loans; business aviation and subscription financing services; and mortgage and other lending products. In addition, the company provides trust and wealth services, such as personal trusts, custodial accounts, investment management accounts, and retirement accounts, as well as corporate trust services, including trustee, paying agent and registered transfer agent services, and other related services. Further, it offers treasury management services comprising automated clearing house, wire transfer, transaction reporting, wholesale lockbox, remote deposit capture, automated credit line transfer, reconciliation, positive pay, merchant and commercial card, and other services, as well as zero balance and investment sweep accounts. Additionally, the company provides ATMs; telephone, online, and mobile banking services; debit and credit cards; safe deposit boxes; and other products and services, as well as processes merchant debit and credit card transactions. The company was formerly known as Bank of the Ozarks and changed its name to Bank OZK in July 2018. Bank OZK was founded in 1903 and is headquartered in Little Rock, Arkansas.
Earnings Per Share
As for profitability, Bank OZK has a trailing twelve months EPS of $6.02.
PE Ratio
Bank OZK has a trailing twelve months price to earnings ratio of 6.63. Meaning, the purchaser of the share is investing $6.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.74%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 2.7% and a drop 2% for the next.
Moving Average
Bank OZK’s worth is below its 50-day moving average of $42.79 and below its 200-day moving average of $44.11.
Volume
Today’s last reported volume for Bank OZK is 1095860 which is 18.91% below its average volume of 1351450.
